China Biotech Services Holdings Limited Announces Strategic Cooperation Framework Agreement with Astrazeneca Investment Co., Ltd
commercialisation and licensing of immune cell therapy; (ii) design, planning and ecological construction of the R&D and production base; and (iii) cooperation models with innovative platforms (the "Cooperation"). Term: Two (2) years from the date on which the Framework Agreement is signed. The Parties specifically agreed to cooperate on the following (among other matters): the Parties will actively discuss immune cell therapy cooperation with a "patient-centered" approach, and conduct in-depth discussions on technology licensing cooperation and commercial development around the fourth-generation costimulation-enhanced CAR T-OX40 development platform developed by Shanghai Longyao Biotech Company Limited; the Parties will conduct in-depth discussions on the design, planning and ecological constructions of an immune cell new drug R&D and production base; and the Parties will actively explore cooperation model with AstraZeneca's global life sciences innovation incubation platform and innovation park. AstraZeneca (China) has built a strategic source and health innovation ecosystem in China that integrates R&D, production, operations, innovation, capital and talents. Shanghai Longyao is one of the pioneers in China to develop CD20-directed autologous chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignances.